| Project/Area Number |
15K10212
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Cardiovascular surgery
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
宮川 繁 大阪大学, 医学系研究科, 特任教授(常勤) (70544237)
福嶌 五月 国立研究開発法人国立循環器病研究センター, 病院, 医長 (80596867)
秦 広樹 大阪大学, 医学系研究科, 講師 (80638198)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2016: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 心不全治療 / 再生医療 / 移植後拒絶反応 / iPS細胞 / MHC適合移植 / 免疫学的拒絶反応 |
|---|
| Outline of Final Research Achievements |
MHC-matched transplantation using homozygous MHC haplotype iPSC-CMs displayed better engraftment and less immune-cell infiltration in the graft in MHC-mismatched transplantation. However, MHC-matched transplantation with single or no immune-suppressive drugs still induced a substantial host immune
response to the graft. Thus, the immunogenicity of allogeneic iPSC-CMs was reduced by MHC-matched transplantation although arequirement for appropriate immune suppression was retained for successful engraftment. Although MHC-homo-iPSCs are preferred to avoid immune rejection, MHC-mismatched iPSC-CMs can also induce comparable cardiac functional recovery at late follow-up, suggesting that MHC-mismatched iPSC-basedcardiac regenerative therapy with immunosuppressants may be a feasible option for treating heart failure in clinical setting.
|
